A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
← catalyst calendarNCT05208762 · readout in 504 d
Sponsored by Seagen, a wholly owned subsidiary of Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
714estimated
Sites
62
Countries
Belgium, Canada, China +8
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-10-25 | actual | When the study began enrolling |
| Primary completion | 2028-01-05 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-01-04 | estimated | The whole study's end, after follow-up |
| First posted | 2022-01-26 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Carcinoma, Non-Small-Cell Lung
- Squamous Cell Carcinoma of the Head and Neck
- Esophageal Squamous Cell Carcinoma
- Triple Negative Breast Neoplasms
- Gastric Cancer
- Endometrial Cancer
- Pancreatic Adenocarcinoma
- Hepatocellular Carcinoma
Interventions
- Drug: PF-08046054 — also filed as SGN-PDL1V
- Drug: pembrolizumab — also filed as Keytruda
Primary outcomes
what the primary-completion date above is the date OFNumber of participants with adverse events (AEs)
measured Through approximately 90 days after last study treatment; up to 3 years
Number of participants with laboratory abnormalities
measured Through approximately 90 days after last study treatment; up to 3 years
Number of participants with dose-limiting toxicities (DLTs)
measured Through the first cycle of study treatment; approximately 1 month
Number of participants with DLTs by dose level
measured Through the first cycle of study treatment; approximately 1 month
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed